Drug-resistant tuberculosis: Difference between revisions
From IDWiki
m (Aidan moved page Multi-drug-resistant tuberculosis to Drug-resistant tuberculosis) |
(added classification) |
||
| Line 1: | Line 1: | ||
* [[Mycobacterium tuberculosis]] infection that is resistant to both first-line drugs, isoniazid and rifampin |
* [[Mycobacterium tuberculosis]] infection that is resistant to both first-line drugs, isoniazid and rifampin |
||
== |
== Classification == |
||
* '''Multidrug resistant tuberculosis (MDR-TB))''': resistance to [[isoniazid]] and [[rifampicin]] |
|||
* '''Extensively drug-resistant tuberculosis (XDR-TB)''': resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables |
|||
* '''Totally drug-resistant tuberculosis (TDR-TB)''': not well-defined |
|||
== Management == |
|||
* 8 months of an intensive four-drug regimen that includes any four drugs to which it is susceptible, in order of preference: |
* 8 months of an intensive four-drug regimen that includes any four drugs to which it is susceptible, in order of preference: |
||
** Any first-line agents to which it is still susceptible |
** Any first-line agents to which it is still susceptible |
||
Revision as of 14:36, 14 November 2019
- Mycobacterium tuberculosis infection that is resistant to both first-line drugs, isoniazid and rifampin
Classification
- Multidrug resistant tuberculosis (MDR-TB)): resistance to isoniazid and rifampicin
- Extensively drug-resistant tuberculosis (XDR-TB): resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables
- Totally drug-resistant tuberculosis (TDR-TB): not well-defined
Management
- 8 months of an intensive four-drug regimen that includes any four drugs to which it is susceptible, in order of preference:
- Any first-line agents to which it is still susceptible
- A fluoroquinolone (except ciprofloxacin)
- An injectable: kanamycin, or other parenteral agent
- Other second-line agents, starting with ethionamide
- Followed by 12 months of a less intensive regimen (at least three effective drugs), for a total of at least 20 months
